Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response
Abstract
:1. Introduction
2. Immunological Assays
Description | Limitations | |
---|---|---|
Multimer Assay |
|
|
T cell proliferation assay |
|
|
Cytotoxic T Lymphocyte Assays | ||
51Chromium release assay (CRA) |
|
|
Caspase 3 Assay |
|
|
Cytokine Production Assays | ||
ELISPOT |
|
|
Intracellular Cytokine Staining |
|
|
ELISA |
|
|
RT-PCR |
|
|
Regulatory T cells |
|
|
Delayed Type Hypersensitivity |
|
|
Humoral Response |
|
|
Tumor infiltrate lymphcoytes |
|
|
2.1. Delayed-Type Hypersensitivity
2.2. Multimer Assays
2.3. T-Cell Proliferation Assays
2.4. Cytotoxic T Lymphocyte Assays
2.5. Cytokine Production Assays
2.6. Immunosuppression Assays
2.7. Humoral Response
3. Promising Techniques That May Suggest Potential Benefit from Immune-Based Therapies
3.1. Immune Infiltrates in Tumors
3.2. Tumor Growth Rates
4. Conclusions
Acknowledgements
References
- Kantoff, P.W.; Higano, C.S.; Shore, N.D.; Berger, E.R.; Small, E.J.; Penson, D.F.; Redfern, C.H.; Ferrari, A.C.; Dreicer, R.; Sims, R.B.; et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010, 363, 411–422. [Google Scholar] [CrossRef]
- Hodi, F.S.; O’Day, S.J.; McDermott, D.F.; Weber, R.W.; Sosman, J.A.; Haanen, J.B.; Gonzalez, R.; Robert, C.; Schadendorf, D.; Hassel, J.C.; et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363, 711–723. [Google Scholar] [CrossRef]
- Kantoff, P.W.; Schuetz, T.J.; Blumenstein, B.A.; Glode, L.M.; Bilhartz, D.L.; Wyand, M.; Manson, K.; Panicali, D.L.; Laus, R.; Schlom, J.; et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J. Clin. Oncol. 2010, 28, 1099–1105. [Google Scholar]
- Madan, R.A.; Gulley, J.L.; Fojo, T.; Dahut, W.L. Therapeutic cancer vaccines in prostate cancer: the paradox of improved survival without changes in time to progression. Oncologist 2010, 15, 969–975. [Google Scholar] [CrossRef]
- Cher, D.J.; Mosmann, T.R. Two types of murine helper T cell clone. II. Delayed-type hypersensitivity is mediated by TH1 clones. J. Immunol. 1987, 138, 3688–3694. [Google Scholar]
- Aarntzen, E.H.; Figdor, C.G.; Adema, G.J.; Punt, C.J.; de Vries, I.J. Dendritic cell vaccination and immune monitoring. Cancer Immunol. Immunother. 2008, 57, 1559–1568. [Google Scholar]
- Disis, M.L.; Schiffman, K.; Gooley, T.A.; McNeel, D.G.; Rinn, K.; Knutson, K.L. Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin. Cancer Res. 2000, 6, 1347–1350. [Google Scholar]
- Nestle, F.O.; Alijagic, S.; Gilliet, M.; Sun, Y.; Grabbe, S.; Dummer, R.; Burg, G.; Schadendorf, D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 1998, 4, 328–332. [Google Scholar] [CrossRef]
- Thomas-Kaskel, A.K.; Zeiser, R.; Jochim, R.; Robbel, C.; Schultze-Seemann, W.; Waller, C.F.; Veelken, H. Vaccination of advanced prostate cancer patients with PSCA and PSA peptide-loaded dendritic cells induces DTH responses that correlate with superior overall survival. Int. J. Cancer 2006, 119, 2428–2434. [Google Scholar] [CrossRef]
- Thurner, B.; Haendle, I.; Roder, C.; Dieckmann, D.; Keikavoussi, P.; Jonuleit, H.; Bender, A.; Maczek, C.; Schreiner, D.; von den Driesch, P.; et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 1999, 190, 1669–1678. [Google Scholar] [CrossRef]
- Morse, M.A.; Deng, Y.; Coleman, D.; Hull, S.; Kitrell-Fisher, E.; Nair, S.; Schlom, J.; Ryback, M.E.; Lyerly, H.K. A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin. Cancer Res. 1999, 5, 1331–1338. [Google Scholar]
- Perambakam, S.; Hallmeyer, S.; Reddy, S.; Mahmud, N.; Bressler, L.; DeChristopher, P.; Mahmud, D.; Nunez, R.; Sosman, J.A.; Peace, D.J. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol. Immunother. 2006, 55, 1033–1042. [Google Scholar]
- Lopez, M.N.; Pereda, C.; Segal, G.; Munoz, L.; Aguilera, R.; Gonzalez, F.E.; Escobar, A.; Ginesta, A.; Reyes, D.; Gonzalez, R.; et al. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells. J. Clin. Oncol. 2009, 27, 945–952. [Google Scholar] [CrossRef]
- Altman, J.D.; Moss, P.A.; Goulder, P.J.; Barouch, D.H.; McHeyzer-Williams, M.G.; Bell, J.I.; McMichael, A.J.; Davis, M.M. Phenotypic analysis of antigen-specific T lymphocytes. Science 1996, 274, 94–96. [Google Scholar] [CrossRef]
- Hampl, J.; Chien, Y.H.; Davis, M.M. CD4 augments the response of a T cell to agonist but not to antagonist ligands. Immunity 1997, 7, 379–385. [Google Scholar]
- Krogsgaard, M.; Li, Q.J.; Sumen, C.; Huppa, J.B.; Huse, M.; Davis, M.M. Agonist/endogenous peptide-MHC heterodimers drive T cell activation and sensitivity. Nature 2005, 434, 238–243. [Google Scholar] [CrossRef]
- Cochran, J.R.; Cameron, T.O.; Stern, L.J. The relationship of MHC-peptide binding and T cell activation probed using chemically defined MHC class II oligomers. Immunity 2000, 12, 241–250. [Google Scholar] [CrossRef]
- Konig, R.; Shen, X.; Germain, R.N. Involvement of both major histocompatibility complex class II alpha and beta chains in CD4 function indicates a role for ordered oligomerization in T cell activation. J. Exp. Med. 1995, 182, 779–787. [Google Scholar] [CrossRef]
- Barnes, E.; Ward, S.M.; Kasprowicz, V.O.; Dusheiko, G.; Klenerman, P.; Lucas, M. Ultra-sensitive class I tetramer analysis reveals previously undetectable populations of antiviral CD8+ T cells. Eur. J. Immunol. 2004, 34, 1570–1577. [Google Scholar] [CrossRef]
- Perambakam, S.; Xie, H.; Edassery, S.; Peace, D.J. Long-term follow-up of HLA-A2+ patients with high-risk, hormone-sensitive prostate cancer vaccinated with the prostate specific antigen peptide homologue (PSA146-154). Clin. Dev. Immunol. 2010, 2010, 473453. [Google Scholar]
- Scher, H.I.; Eisenberger, M.; D’Amico, A.V.; Halabi, S.; Small, E.J.; Morris, M.; Kattan, M.W.; Roach, M.; Kantoff, P.; Pienta, K.J.; et al. Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: Recommendations from the Prostate-Specific Antigen Working Group. J. Clin. Oncol. 2004, 22, 537–556. [Google Scholar]
- Weber, J.S.; Vogelzang, N.J.; Ernstoff, M.S.; Goodman, O.B.; Cranmer, L.D.; Marshall, J.L.; Miles, S.; Rosario, D.; Diamond, D.C.; Qiu, Z.; et al. A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors. J. Immunother. 2011, 34, 556–567. [Google Scholar] [CrossRef]
- Dangoor, A.; Lorigan, P.; Keilholz, U.; Schadendorf, D.; Harris, A.; Ottensmeier, C.; Smyth, J.; Hoffmann, K.; Anderson, R.; Cripps, M.; et al. Clinical and immunological responses in metastatic melanoma patients vaccinated with a high-dose poly-epitope vaccine. Cancer Immunol. Immunother. 2010, 59, 863–873. [Google Scholar] [CrossRef]
- Froebel, K.S.; Pakker, N.G.; Aiuti, F.; Bofill, M.; Choremi-Papadopoulou, H.; Economidou, J.; Rabian, C.; Roos, M.T.; Ryder, L.P.; Miedema, F.; et al. Standardisation and quality assurance of lymphocyte proliferation assays for use in the assessment of immune function. European Concerted Action on Immunological and Virological Markers of HIV Disease Progression. J. Immunol. Methods 1999, 227, 85–97. [Google Scholar] [CrossRef]
- Beer, T.M.; Bernstein, G.T.; Corman, J.M.; Glode, L.M.; Hall, S.J.; Poll, W.L.; Schellhammer, P.F.; Jones, L.A.; Xu, Y.; Kylstra, J.W.; et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin. Cancer Res. 2011, 17, 4558–4567. [Google Scholar]
- Johnson, L.E.; Frye, T.P.; Arnot, A.R.; Marquette, C.; Couture, L.A.; Gendron-Fitzpatrick, A.; McNeel, D.G. Safety and immunological efficacy of a prostate cancer plasmid DNA vaccine encoding prostatic acid phosphatase (PAP). Vaccine 2006, 24, 293–303. [Google Scholar]
- McNeel, D.G.; Dunphy, E.J.; Davies, J.G.; Frye, T.P.; Johnson, L.E.; Staab, M.J.; Horvath, D.L.; Straus, J.; Alberti, D.; Marnocha, R.; et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J. Clin. Oncol. 2009, 27, 4047–4054. [Google Scholar] [CrossRef]
- Sheikh, N.A.; Petrylak, D.; Kantoff, P.W.; Dela Rosa, C.; Stewart, F.P.; Kuan, L.Y.; Whitmore, J.B.; Trager, J.B.; Poehlein, C.H.; Frohlich, M.W.; et al. Sipuleucel-T immune parameters correlate with survival: An analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol. Immunother. 2012. [Google Scholar]
- Burleson, G.R.; Burleson, F.G.; Dietert, R.R. The cytotoxic T lymphocyte assay for evaluating cell-mediated immune function. Methods Mol. Biol. 2010, 598, 195–205. [Google Scholar]
- Liu, L.; Chahroudi, A.; Silvestri, G.; Wernett, M.E.; Kaiser, W.J.; Safrit, J.T.; Komoriya, A.; Altman, J.D.; Packard, B.Z.; Feinberg, M.B. Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat. Med. 2002, 8, 185–189. [Google Scholar] [CrossRef]
- Berke, G. The CTL’s kiss of death. Cell 1995, 81, 9–12. [Google Scholar] [CrossRef]
- Henkart, P.A.; Williams, M.S.; Zacharchuk, C.M.; Sarin, A. Do CTL kill target cells by inducing apoptosis? Semin. Immunol. 1997, 9, 135–144. [Google Scholar] [CrossRef]
- Jerome, K.R.; Sloan, D.D.; Aubert, M. Measuring T-cell-mediated cytotoxicity using antibody to activated caspase 3. Nat. Med. 2003, 9, 4–5. [Google Scholar] [CrossRef]
- Koido, S.; Hara, E.; Homma, S.; Torii, A.; Toyama, Y.; Kawahara, H.; Watanabe, M.; Yanaga, K.; Fujise, K.; Tajiri, H.; et al. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin. Cancer Res. 2005, 11, 7891–7900. [Google Scholar]
- Jerome, K.R.; Sloan, D.D.; Aubert, M. Measurement of CTL-induced cytotoxicity: The caspase 3 assay. Apoptosis 2003, 8, 563–571. [Google Scholar] [CrossRef]
- Zumkeller, W.; Schofield, P.N. Growth factors, cytokines and soluble forms of receptor molecules in cancer patients. Anticancer Res. 1995, 15, 343–348. [Google Scholar]
- Tanguay, S.; Killion, J.J. Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells. Lymphokine Cytokine Res. 1994, 13, 259–263. [Google Scholar]
- Ronnelid, J.; Klareskog, L. A comparison between ELISPOT methods for the detection of cytokine producing cells: Greater sensitivity and specificity using ELISA plates as compared to nitrocellulose membranes. J. Immunol. Methods 1997, 200, 17–26. [Google Scholar] [CrossRef]
- Czerkinsky, C.; Andersson, G.; Ekre, H.P.; Nilsson, L.A.; Klareskog, L.; Ouchterlony, O. Reverse ELISPOT assay for clonal analysis of cytokine production. I. Enumeration of gamma-interferon-secreting cells. J. Immunol. Methods 1988, 110, 29–36. [Google Scholar]
- Whiteside, T. ELISPOT assay assessment of cellular immune responses to anti-cancer vaccine. In Analysis of T Cell Response How to Analyze Cellular Immune Responses against Tumor Associated Antigens; Nagorsen, D., Marincola, F.M., Eds.; Springer: Dordrecht, The Netherlands, 2005; pp. 143–155. [Google Scholar]
- Asai, T.; Storkus, W.J.; Whiteside, T.L. Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines. Clin. Diagn. Lab. Immunol. 2000, 7, 145–154. [Google Scholar]
- Ryan, J.E.; Ovsyannikova, I.G.; Dhiman, N.; Pinsky, N.A.; Vierkant, R.A.; Jacobson, R.M.; Poland, G.A. Inter-operator variation in ELISPOT analysis of measles virus-specific IFN-gamma-secreting T cells. Scand. J. Clin. Lab. Invest. 2005, 65, 681–689. [Google Scholar]
- Cox, J.H.; Ferrari, G.; Kalams, S.A.; Lopaczynski, W.; Oden, N.; D’Souza M, P. Results of an ELISPOT proficiency panel conducted in 11 laboratories participating in international human immunodeficiency virus type 1 vaccine trials. AIDS Res. Hum. Retroviruses. 2005, 21, 68–81. [Google Scholar] [CrossRef]
- Britten, C.M.; Meyer, R.G.; Kreer, T.; Drexler, I.; Wolfel, T.; Herr, W. The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays. J. Immunol. Methods 2002, 259, 95–110. [Google Scholar] [CrossRef]
- Almeida, C.A.; Roberts, S.G.; Laird, R.; McKinnon, E.; Ahmed, I.; Pfafferott, K.; Turley, J.; Keane, N.M.; Lucas, A.; Rushton, B.; et al. Automation of the ELISpot assay for high-throughput detection of antigen-specific T-cell responses. J. Immunol. Methods 2009, 344, 1–5. [Google Scholar] [CrossRef]
- Hernandez-Fuentes, M.P.; Warrens, A.N.; Lechler, R.I. Immunologic monitoring. Immunol. Rev. 2003, 196, 247–264. [Google Scholar] [CrossRef]
- Sander, B.; Andersson, J.; Andersson, U. Assessment of cytokines by immunofluorescence and the paraformaldehyde-saponin procedure. Immunol. Rev. 1991, 119, 65–93. [Google Scholar] [CrossRef]
- Leng, S.X.; McElhaney, J.E.; Walston, J.D.; Xie, D.; Fedarko, N.S.; Kuchel, G.A. ELISA and multiplex technologies for cytokine measurement in inflammation and aging research. J. Gerontol. A Biol. Sci. Med. Sci. 2008, 63, 879–884. [Google Scholar] [CrossRef]
- Aziz, N.; Nishanian, P.; Mitsuyasu, R.; Detels, R.; Fahey, J.L. Variables that affect assays for plasma cytokines and soluble activation markers. Clin. Diagn. Lab. Immunol. 1999, 6, 89–95. [Google Scholar]
- Toellner, K.M.; Scheel-Toellner, D.; Seitzer, U.; Sprenger, R.; Trumper, L.; Schluter, C.; Flad, H.D.; Gerdes, J. The use of reverse transcription polymerase chain reaction to analyse large numbers of mRNA species from a single cell. J. Immunol. Methods 1996, 191, 71–75. [Google Scholar] [CrossRef]
- Smyth, M.J.; Dunn, G.P.; Schreiber, R.D. Cancer immunosurveillance and immunoediting: The roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv. Immunol. 2006, 90, 1–50. [Google Scholar] [CrossRef]
- Miyara, M.; Sakaguchi, S. Natural regulatory T cells: Mechanisms of suppression. Trends Mol. Med. 2007, 13, 108–116. [Google Scholar]
- Nagaraj, S.; Gabrilovich, D.I. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 2008, 68, 2561–2563. [Google Scholar] [CrossRef]
- Mantovani, A.; Schioppa, T.; Porta, C.; Allavena, P.; Sica, A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006, 25, 315–322. [Google Scholar] [CrossRef]
- Fassnacht, M.; Lee, J.; Milazzo, C.; Boczkowski, D.; Su, Z.; Nair, S.; Gilboa, E. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: Implication for cancer immunotherapy. Clin. Cancer Res. 2005, 11, 5566–5571. [Google Scholar] [CrossRef]
- Shurin, M.R.; Yurkovetsky, Z.R.; Tourkova, I.L.; Balkir, L.; Shurin, G.V. Inhibition of CD40 expression and CD40-mediated dendritic cell function by tumor-derived IL-10. Int. J. Cancer 2002, 101, 61–68. [Google Scholar] [CrossRef]
- Elgert, K.D.; Alleva, D.G.; Mullins, D.W. Tumor-induced immune dysfunction: The macrophage connection. J. Leukoc. Biol. 1998, 64, 275–290. [Google Scholar]
- Uyttenhove, C.; Pilotte, L.; Theate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; van den Eynde, B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med. 2003, 9, 1269–1274. [Google Scholar] [CrossRef]
- Fricke, I.; Mirza, N.; Dupont, J.; Lockhart, C.; Jackson, A.; Lee, J.H.; Sosman, J.A.; Gabrilovich, D.I. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res. 2007, 13, 4840–4848. [Google Scholar] [CrossRef]
- Takeda, K.; Kojima, Y.; Uno, T.; Hayakawa, Y.; Teng, M.W.; Yoshizawa, H.; Yagita, H.; Gejyo, F.; Okumura, K.; Smyth, M.J. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules. J. Immunol. 2010, 184, 5493–5501. [Google Scholar]
- Ohta, T.; Elnemr, A.; Kitagawa, H.; Kayahara, M.; Takamura, H.; Fujimura, T.; Nishimura, G.; Shimizu, K.; Yi, S.Q.; Miwa, K. Fas ligand expression in human pancreatic cancer. Oncol. Rep. 2004, 12, 749–754. [Google Scholar]
- Hori, S.; Nomura, T.; Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003, 299, 1057–1061. [Google Scholar] [CrossRef]
- Yokokawa, J.; Cereda, V.; Remondo, C.; Gulley, J.L.; Arlen, P.M.; Schlom, J.; Tsang, K.Y. Enhanced functionality of CD4+CD25(high)FoxP3+ regulatory T cells in the peripheral blood of patients with prostate cancer. Clin. Cancer Res. 2008, 14, 1032–1040. [Google Scholar] [CrossRef]
- Gulley, J.L.; Arlen, P.M.; Madan, R.A.; Tsang, K.Y.; Pazdur, M.P.; Skarupa, L.; Jones, J.L.; Poole, D.J.; Higgins, J.P.; Hodge, J.W.; et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol. Immunother. 2010, 59, 663–674. [Google Scholar] [CrossRef]
- Vergati, M.; Cereda, V.; Madan, R.A.; Gulley, J.L.; Huen, N.Y.; Rogers, C.J.; Hance, K.W.; Arlen, P.M.; Schlom, J.; Tsang, K.Y. Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination. Cancer Immunol. Immunother. 2011, 60, 197–206. [Google Scholar] [CrossRef]
- Zhang, Y.; Campbell, C.; Li, Q.; Gildersleeve, J.C. Multidimensional glycan arrays for enhanced antibody profiling. Mol. Biosyst. 2010, 6, 1583–1591. [Google Scholar]
- Fong, L.; Weinberg, V.K.; Chan, S.E.; Corman, J.M.; Amling, C.L.; Stephenson, R.A.; Formaker, C.; Simko, J.; Sims, R.B.; Carroll, P.; et al. Neoadjuvant sipuleucel-T in localized prostate cancer: Effects on immune cells within the prostate tumor microenvironment. J. Clin. Oncol. 2012, 30. Abstract 2564. [Google Scholar]
- Lu, C.; Williams, A.K.; Chalasani, V.; Martinez, C.H.; Chin, J. Immunotherapy for metastatic prostate cancer: Where are we at with sipuleucel-T? Expert Opin. Biol. Ther. 2011, 11, 99–108. [Google Scholar] [CrossRef]
- Zhang, L.; Conejo-Garcia, J.R.; Katsaros, D.; Gimotty, P.A.; Massobrio, M.; Regnani, G.; Makrigiannakis, A.; Gray, H.; Schlienger, K.; Liebman, M.N.; et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003, 348, 203–213. [Google Scholar]
- Kondratiev, S.; Sabo, E.; Yakirevich, E.; Lavie, O.; Resnick, M.B. Intratumoral CD8+ T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin. Cancer Res. 2004, 10, 4450–4456. [Google Scholar]
- Ladanyi, A.; Kiss, J.; Somlai, B.; Gilde, K.; Fejos, Z.; Mohos, A.; Gaudi, I.; Timar, J. Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol. Immunother. 2007, 56, 1459–1469. [Google Scholar] [CrossRef]
- Pages, F.; Kirilovsky, A.; Mlecnik, B.; Asslaber, M.; Tosolini, M.; Bindea, G.; Lagorce, C.; Wind, P.; Marliot, F.; Bruneval, P.; et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J. Clin. Oncol. 2009, 27, 5944–5951. [Google Scholar]
- Pages, F.; Berger, A.; Camus, M.; Sanchez-Cabo, F.; Costes, A.; Molidor, R.; Mlecnik, B.; Kirilovsky, A.; Nilsson, M.; Damotte, D.; et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 2005, 353, 2654–2666. [Google Scholar]
- Yamada, N.; Oizumi, S.; Kikuchi, E.; Shinagawa, N.; Konishi-Sakakibara, J.; Ishimine, A.; Aoe, K.; Gemba, K.; Kishimoto, T.; Torigoe, T.; et al. CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection. Cancer Immunol. Immunother. 2010, 59, 1543–1549. [Google Scholar]
- Bates, G.J.; Fox, S.B.; Han, C.; Leek, R.D.; Garcia, J.F.; Harris, A.L.; Banham, A.H. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J. Clin. Oncol. 2006, 24, 5373–5380. [Google Scholar] [CrossRef]
- Shimizu, K.; Nakata, M.; Hirami, Y.; Yukawa, T.; Maeda, A.; Tanemoto, K. Tumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancer. J. Thorac. Oncol. 2010, 5, 585–590. [Google Scholar]
- Shen, Z.; Zhou, S.; Wang, Y.; Li, R.L.; Zhong, C.; Liang, C.; Sun, Y. Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/CD8+ ratio are associated with adverse prognosis in resectable gastric cancer. J. Cancer Res. Clin. Oncol. 2010, 136, 1585–1595. [Google Scholar] [CrossRef]
- Liotta, F.; Gacci, M.; Frosali, F.; Querci, V.; Vittori, G.; Lapini, A.; Santarlasci, V.; Serni, S.; Cosmi, L.; Maggi, L.; et al. Frequency of regulatory T cells in peripheral blood and in tumour-infiltrating lymphocytes correlates with poor prognosis in renal cell carcinoma. BJU Int. 2011, 107, 1500–1506. [Google Scholar]
- Heery, C.; Pinto, P.; Schlom, J.; Tsang, K.; Madan, R.; Poole, D.; Vergati, M.; Walter Rodriguez, B.; Merino, M.; Gulley, J. Intraprostatic vaccine administration in patients with locally recurrent prostate cancer. J. Clin. Oncol. 2011, 29. Abstract 141.. [Google Scholar]
- Stein, W.D.; Gulley, J.L.; Schlom, J.; Madan, R.A.; Dahut, W.; Figg, W.D.; Ning, Y.M.; Arlen, P.M.; Price, D.; Bates, S.E.; et al. Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: The growth rate constant as an indicator of therapeutic efficacy. Clin. Cancer Res. 2011, 17, 907–917. [Google Scholar]
- Stein, W.D.; Figg, W.D.; Dahut, W.; Stein, A.D.; Hoshen, M.B.; Price, D.; Bates, S.E.; Fojo, T. Tumor growth rates derived from data for patients in a clinical trial correlate strongly with patient survival: A novel strategy for evaluation of clinical trial data. Oncologist 2008, 13, 1046–1054. [Google Scholar] [CrossRef]
- Gulley, J.L.; Madan, R.A.; Schlom, J. Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr. Oncol. 2011, 18, e150–e157. [Google Scholar]
© 2012 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Kim, J.W.; Bilusic, M.; Heery, C.J.; Madan, R.A. Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response. Cancers 2012, 4, 1229-1246. https://doi.org/10.3390/cancers4041229
Kim JW, Bilusic M, Heery CJ, Madan RA. Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response. Cancers. 2012; 4(4):1229-1246. https://doi.org/10.3390/cancers4041229
Chicago/Turabian StyleKim, Joseph W., Marijo Bilusic, Christopher J. Heery, and Ravi A. Madan. 2012. "Therapeutic Cancer Vaccines in Prostate Cancer: The Quest for Intermediate Markers of Response" Cancers 4, no. 4: 1229-1246. https://doi.org/10.3390/cancers4041229